Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TNF in Melanoma Patients Treated With Immunotherapy

Next Previous
Search
Trial Profile

TNF in Melanoma Patients Treated With Immunotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MELANFalpha

    • Most Recent Events

    • 13 Sep 2022 Primary endpoint (The primary endpoint is the discriminant capacity to predict progression at 12 weeks evaluated using RECIST V1.1 criteria.) has been met, as per results presented at the 47th European Society for Medical Oncology Congress.
    • 13 Sep 2022 Results assessing the TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors (ipilimumab+nivolumab; pembolizumab or nivolumab), presented at the 47th European Society for Medical Oncology Congress.
    • 23 Nov 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top